home / stock / atnm / atnm quote
Last: | $7.83 |
---|---|
Change Percent: | -0.5% |
Open: | $7.98 |
Close: | $7.83 |
High: | $8.19 |
Low: | $7.72 |
Volume: | 555,970 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.83 | $7.98 | $7.83 | $8.19 | $7.72 | 555,970 | 03-28-2024 |
$7.94 | $8.08 | $7.94 | $8.34 | $7.89 | 470,357 | 03-27-2024 |
$8.12 | $8.77 | $8.12 | $9.05 | $8 | 566,484 | 03-26-2024 |
$8.67 | $9.34 | $8.67 | $9.45 | $8.6 | 549,863 | 03-25-2024 |
$9.2 | $9.15 | $9.2 | $9.8599 | $8.88 | 1,780,421 | 03-22-2024 |
$9.11 | $8.7 | $9.11 | $9.3 | $8.63 | 1,690,199 | 03-21-2024 |
$8.6 | $8.2 | $8.6 | $8.7 | $7.9 | 1,088,038 | 03-20-2024 |
$8.21 | $7.6 | $8.21 | $8.5 | $7.3 | 2,036,255 | 03-19-2024 |
$6.54 | $6.98 | $6.54 | $6.98 | $6.35 | 259,951 | 03-18-2024 |
$6.75 | $6.2 | $6.75 | $6.78 | $6.16 | 331,867 | 03-15-2024 |
$6.27 | $6.73 | $6.27 | $6.87 | $6.22 | 194,258 | 03-14-2024 |
$6.7 | $6.57 | $6.7 | $6.75 | $6.48 | 104,131 | 03-13-2024 |
$6.59 | $6.81 | $6.59 | $7 | $6.58 | 151,677 | 03-12-2024 |
$6.92 | $7.67 | $6.92 | $7.7488 | $6.83 | 244,376 | 03-11-2024 |
$7.65 | $7.61 | $7.65 | $8.03 | $7.51 | 174,888 | 03-08-2024 |
$7.61 | $7.74 | $7.61 | $7.8 | $7.44 | 166,392 | 03-07-2024 |
$7.76 | $7.88 | $7.76 | $8.06 | $7.69 | 90,973 | 03-06-2024 |
$7.77 | $7.75 | $7.77 | $8 | $7.52 | 116,037 | 03-05-2024 |
$7.88 | $8.5 | $7.88 | $8.5 | $7.72 | 263,192 | 03-04-2024 |
$8.47 | $8.49 | $8.47 | $8.5 | $8.17 | 217,579 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy PR Newswire Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a m...
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand PR Newswire Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radi...